相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ineffective erythropoiesis and its treatment
Mario Cazzola
BLOOD (2022)
A novel index to evaluate ineffective erythropoiesis in hematological diseases offers insights into sickle cell disease
John Brewin et al.
HAEMATOLOGICA (2022)
Betibeglogene Autotemcel Gene Therapy for Non-β0/β0 Genotype β-Thalassemia
Franco Locatelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease
Sunita Goyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial
Sanjeev Forsyth et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2022)
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study
Kevin H M Kuo et al.
LANCET (2022)
Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model
Paul J. Schmidt et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia
Naja Nyffenegger et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Erythroferrone structure, function, and physiology: Iron homeostasis and beyond
Daniel N. Srole et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2021)
β-Thalassemias
Ali T. Taher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pursuing Orally Bioavailable Hepcidin Analogues via Cyclic N-Methylated Mini-Hepcidins
Daniela Goncalves Monteiro et al.
BIOMEDICINES (2021)
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia
Jim Vadolas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither
Richard J. Jones et al.
BLOOD (2021)
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development
John Porter et al.
EXPERT REVIEW OF HEMATOLOGY (2021)
The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model
Alessandro Matte et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers
Frank Richard et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
Martina Schuessler-Lenz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major
Carla Casu et al.
HAEMATOLOGICA (2020)
Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from binding to the BMP type I receptor ALK3
Chia-Yu Wang et al.
BLOOD (2020)
Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia
Joao Arezes et al.
BLOOD (2020)
Iron metabolism and iron disorders revisited in the hepcidin era
Clara Camaschella et al.
HAEMATOLOGICA (2020)
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
M. D. Cappellini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity
Carla Casu et al.
BLOOD (2020)
Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms
Christian B. Billesbolle et al.
NATURE (2020)
The Role of Erythroferrone Hormone as Erythroid Regulator of Hepcidin and Iron Metabolism during Thalassemia and in Iron Deficiency Anemia- A Short Review
Tiba Sabah Talawy et al.
JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL (2020)
Erythropoietic regulators of iron metabolism
Tomas Ganz
FREE RADICAL BIOLOGY AND MEDICINE (2019)
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
Rachael F. Grace et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia
Antonio Piga et al.
BLOOD (2019)
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent β-thalassemia
Sarah Marktel et al.
NATURE MEDICINE (2019)
EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update
Achille Iolascon et al.
HEMASPHERE (2019)
Hepcidin, an Iron Regulatory Hormone of Innate Immunity, is Differentially Expressed in Premature Fetuses with Early-Onset Neonatal Sepsis
Sammy M. Tabbah et al.
AMERICAN JOURNAL OF PERINATOLOGY (2018)
Transferrin receptor 2 is a potential novel therapeutic target for beta-thalassemia: evidence from a murine model
Irene Artuso et al.
BLOOD (2018)
Erythroferrone inhibits the induction of hepcidin by BMP6
Joao Arezes et al.
BLOOD (2018)
Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin
Sharraya Aschemeyer et al.
BLOOD (2018)
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin
Maciej W. Garbowski et al.
HAEMATOLOGICA (2017)
Sickle Cell Disease
Frederic B. Piel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin
Maciej W. Garbowski et al.
HAEMATOLOGICA (2017)
Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice
Huihui Li et al.
BLOOD (2017)
Ineffective erythropoiesis and regulation of iron status in iron loading anaemias
Clara Camaschella et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia
Carla Casu et al.
HAEMATOLOGICA (2016)
Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia
Carla Casu et al.
HAEMATOLOGICA (2016)
Regulation of Hepcidin by Erythropoiesis: The Story So Far
Sant-Rayn Pasricha et al.
ANNUAL REVIEW OF NUTRITION, VOL 36 (2016)
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Carla Casu et al.
BLOOD (2016)
Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010
D. Baronciani et al.
BONE MARROW TRANSPLANTATION (2016)
The mutual control of iron and erythropoiesis
C. Camaschella et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2016)
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia
Paul J. Schmidt et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia
Leon Kautz et al.
BLOOD (2015)
Modulation of Hepcidin as Therapy for Primary and Secondary Iron Overload Disorders Preclinical Models and Approaches
Paul J. Schmidt et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Identification of erythroferrone as an erythroid regulator of iron metabolism
Leon Kautz et al.
NATURE GENETICS (2014)
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe-/- mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia
Paul J. Schmidt et al.
BLOOD (2013)
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice
Shuling Guo et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia
Antonella Nai et al.
BLOOD (2012)
Development of Gene Therapy for Thalassemia
Arthur W. Nienhuis et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Adipocyte Hypoxia Increases Hepatocyte Hepcidin Expression
Korry Joseph Hintze et al.
BIOLOGICAL TRACE ELEMENT RESEARCH (2011)
Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis
Hana Forejtnikova et al.
BLOOD (2010)
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice
Sara Gardenghi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Pathophysiology of Transfusional Iron Overload: Contrasting Patterns in Thalassemia Major and Sickle Cell Disease
John B. Porter
HEMOGLOBIN (2009)
Hepcidin expression in mouse retina and its regulation via lipopolysaccharide/Toll-like receptor-4 pathway independent of Hfe
Jaya P. Gnana-Prakasam et al.
BIOCHEMICAL JOURNAL (2008)
Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver
Leon Kautz et al.
BLOOD (2008)
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)
Karin E. Finberg et al.
NATURE GENETICS (2008)
The serine protease TMPRSS6 is required to sense iron deficiency
Xin Du et al.
SCIENCE (2008)
Autocrine formation of hepcidin induces iron retention in human monocytes
Igor Theurl et al.
BLOOD (2008)
Liver iron concentrations and urinary hepcidin in β-thalassemia
Raffaella Origa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Urinary hepcidin in congenital chronic anemias
Susan L. Kearney et al.
PEDIATRIC BLOOD & CANCER (2007)
Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: Changes in iron regulatory protein, hepcidin, and ferritin expression
Zandra A. Jenkins et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2007)
Suppression of hepcidin during anemia requires erythropoietic activity
Mihwa Pak et al.
BLOOD (2006)
The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study
E Nemeth et al.
BLOOD (2006)
Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages
XB Liu et al.
BLOOD CELLS MOLECULES AND DISEASES (2005)
The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney
H Kulaksiz et al.
JOURNAL OF ENDOCRINOLOGY (2005)
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization
E Nemeth et al.
SCIENCE (2004)
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
E Nemeth et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
CH Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity
A Krause et al.
FEBS LETTERS (2000)
分享论文
